VIVUS Announces Positive Results From Phase 2 Study of Qnexa in Obstructive Sleep Apnea

Thursday, January 7, 2010 Research News
Email Print This Page Comment
Font : A-A+

Qnexa Treatment Results in 69% Reduction in Sleep Apnea Events

CONTACT:  

VIVUS, Inc.

Investor Relations:

The Trout Group

Timothy E. Morris

Brian Korb

Chief Financial Officer

646-378-2923

650-934-5200

Media Relations:

Pure Communications, Inc.

Dan Budwick

973-271-6085



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook